BioSpace News Archive

Analysis of results from EMERGE ™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 C ash , cash equivalents and marketable securities of $ 82.1 million as of September 30 , 2020; based on current operating plans, expected to provide runway through end of 2021

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fiscal first quarter of 2021, ended September 30, 2020. First Quarter Highlights Reported U.S based RECELL ® revenue of $5.0 million in the first quarter of 2021, a 59% i

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, reported its financial results for the quarter ended September 30, 2020.

Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq ™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults Launched Upneeq from new operating subsidiary, RVL Pharmaceuticals, enabling broad access for providers and patients Early experience program,

Initiation of Phase 1/2a Trialof CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular DegenerationExpected by Year-End 2020

Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the third quarter ended September 30, 2020. “During the third quarter and subsequent period, we continued to execute on our growth strategy to advance our late-stage ophthalmic portfolio while in parallel securing global development and commercialization pa

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced financial results for the third quarter 2020.

As COVID-19 continues to set new records nationwide, the importance of understanding the difference in accuracy between temporal artery thermometers (TAT) and non-contact devices – now used widely for public temperature screenings – is of paramount importance

Pfizer has announced that early results in its COVID-19 vaccine trial show an astonishing 90 percent efficacy , notes Physicians for Civil Defense. “In 10 years only three other vaccines with efficacy greater than 50 percent have been developed.” Of about 40,000 volunteers who received two doses of the experimental vaccine, 9

PDS Biotechnology Corporation announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.